Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_assertion type Assertion NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_head.
- NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_assertion description "[Despite the clinical efficacy achieved with frontline therapies for BCR-ABL-positive disease, such as imatinib and second-generation ABL inhibitors like nilotinib or dasatinib that were originally designed to override insensitivity to imatinib, drug resistance still remains a challenge, especially for patients with advanced-stage chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_provenance.
- NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_assertion evidence source_evidence_literature NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_provenance.
- NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_assertion SIO_000772 25331939 NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_provenance.
- NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_assertion wasDerivedFrom befree-2016 NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_provenance.
- NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_assertion wasGeneratedBy ECO_0000203 NP1230954.RAANaFFs0In1nDOmja4pLluZ4y6gEJbUVi06SH-y6H0YA130_provenance.